These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 25940030)

  • 1. Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).
    Rapoport B; Chua D; Poma A; Arora S; Wang Y; Fein LE
    Support Care Cancer; 2015 Nov; 23(11):3281-8. PubMed ID: 25940030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.
    Rapoport BL; Chasen MR; Gridelli C; Urban L; Modiano MR; Schnadig ID; Poma A; Arora S; Kansra V; Schwartzberg LS; Navari RM
    Lancet Oncol; 2015 Sep; 16(9):1079-1089. PubMed ID: 26272769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
    Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
    Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy.
    Hesketh PJ; Schnadig ID; Schwartzberg LS; Modiano MR; Jordan K; Arora S; Powers D; Aapro M
    Cancer; 2016 Aug; 122(15):2418-25. PubMed ID: 27176138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy.
    Chasen M; Urban L; Schnadig I; Rapoport B; Powers D; Arora S; Navari R; Schwartzberg L; Gridelli C
    Support Care Cancer; 2017 Jan; 25(1):85-92. PubMed ID: 27557833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
    Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.
    Schwartzberg LS; Modiano MR; Rapoport BL; Chasen MR; Gridelli C; Urban L; Poma A; Arora S; Navari RM; Schnadig ID
    Lancet Oncol; 2015 Sep; 16(9):1071-1078. PubMed ID: 26272768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
    Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
    Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rolapitant: An NK-1 Receptor Antagonist for the Prevention of Chemotherapy- Induced Nausea and Vomiting.
    Rapoport BL
    Rev Recent Clin Trials; 2017; 12(3):193-201. PubMed ID: 28393710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of safety and efficacy of rolapitant, NK-1 receptor antagonist for prevention of chemotherapy-induced nausea and vomiting.
    Ahmed H; Hammad AM; Abushouk AI; Zidan M; Salem M; Negida A; Abdel-Daim MM
    Curr Probl Cancer; 2018; 42(2):241-255. PubMed ID: 29310827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations.
    Rapoport BL; Aapro M; Chasen MR; Jordan K; Navari RM; Schnadig I; Schwartzberg L
    Drug Des Devel Ther; 2017; 11():2621-2629. PubMed ID: 28919712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rolapitant for the prevention of delayed nausea and vomiting over initial and repeat courses of emetogenic chemotherapy.
    Rapoport B; van Eeden R; Smit T
    Expert Rev Clin Pharmacol; 2017 Jan; 10(1):17-29. PubMed ID: 27894202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV).
    Rashad N; Abdel-Rahman O
    Drug Des Devel Ther; 2017; 11():947-954. PubMed ID: 28392676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rolapitant: A Review in Chemotherapy-Induced Nausea and Vomiting.
    Heo YA; Deeks ED
    Drugs; 2017 Oct; 77(15):1687-1694. PubMed ID: 28929404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).
    Rojas C; Slusher BS
    Cancer Treat Rev; 2015 Dec; 41(10):904-13. PubMed ID: 26442475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
    A Mahrous M; A El-Azab G; A Tawfik H
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetics of Rolapitant in Patients With Chemotherapy-Induced Nausea and Vomiting.
    Wang X; Wang J; Zhang ZY; Kansra V
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):850-860. PubMed ID: 31418538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial.
    Herrstedt J; Summers Y; Jordan K; von Pawel J; Jakobsen AH; Ewertz M; Chan S; Naik JD; Karthaus M; Dubey S; Davis R; Fox GM
    Support Care Cancer; 2019 Jul; 27(7):2699-2705. PubMed ID: 30488222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence.
    Chasen MR; Rapoport BL
    Future Oncol; 2016 Mar; 12(6):763-78. PubMed ID: 26842387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.